Mark Lewis, Director of Gastrointestinal Oncology at Intermountain Healthcare in Utah, posted on X:
“Dr James Yao observes that, prior to 2011, the only FDA-approved systemic therapy for pancreatic neuroendocrine tumors was streptozocin!
What a remarkable decade-plus of progress in the field and yet, for our patients, we have miles to go before we sleep.”
More posts featuring Pancreatic Cancer.